Boosting therapeutic potency of antibodies by taming Fc domain functions
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Tae Hyun | - |
dc.contributor.author | Jung, Sang Taek | - |
dc.date.accessioned | 2021-08-31T23:04:28Z | - |
dc.date.available | 2021-08-31T23:04:28Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-11-18 | - |
dc.identifier.issn | 1226-3613 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/61570 | - |
dc.description.abstract | Monoclonal antibodies (mAbs) are one of the most widely used drug platforms for infectious diseases or cancer therapeutics because they selectively target pathogens, infectious cells, cancerous cells, and even immune cells. In this way, they mediate the elimination of target molecules and cells with fewer side effects than other therapeutic modalities. In particular, cancer therapeutic mAbs can recognize cell-surface proteins on target cells and then kill the targeted cells by multiple mechanisms that are dependent upon a fragment crystallizable (Fc) domain interacting with effector Fc gamma receptors, including antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis. Extensive engineering efforts have been made toward tuning Fc functions by either reinforcing (e.g. for targeted therapy) or disabling (e.g. for immune checkpoint blockade therapy) effector functions and prolonging the serum half-lives of antibodies, as necessary. In this report, we review Fc engineering efforts to improve therapeutic potency, and propose future antibody engineering directions that can fulfill unmet medical needs. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | NATURE PUBLISHING GROUP | - |
dc.subject | I-RELATED RECEPTOR | - |
dc.subject | FAMILIAL HYPERCATABOLIC HYPOPROTEINEMIA | - |
dc.subject | HUMAN IGG1 | - |
dc.subject | MONOCLONAL-ANTIBODY | - |
dc.subject | STRUCTURAL-CHARACTERIZATION | - |
dc.subject | BINDING-SITE | - |
dc.subject | HEMOPHILIA-A | - |
dc.subject | GAMMA-RIII | - |
dc.subject | EMICIZUMAB PROPHYLAXIS | - |
dc.subject | CD20 IMMUNOTHERAPY | - |
dc.title | Boosting therapeutic potency of antibodies by taming Fc domain functions | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Sang Taek | - |
dc.identifier.doi | 10.1038/s12276-019-0345-9 | - |
dc.identifier.scopusid | 2-s2.0-85075114343 | - |
dc.identifier.wosid | 000497803000002 | - |
dc.identifier.bibliographicCitation | EXPERIMENTAL AND MOLECULAR MEDICINE, v.51 | - |
dc.relation.isPartOf | EXPERIMENTAL AND MOLECULAR MEDICINE | - |
dc.citation.title | EXPERIMENTAL AND MOLECULAR MEDICINE | - |
dc.citation.volume | 51 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002528371 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | I-RELATED RECEPTOR | - |
dc.subject.keywordPlus | FAMILIAL HYPERCATABOLIC HYPOPROTEINEMIA | - |
dc.subject.keywordPlus | HUMAN IGG1 | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | STRUCTURAL-CHARACTERIZATION | - |
dc.subject.keywordPlus | BINDING-SITE | - |
dc.subject.keywordPlus | HEMOPHILIA-A | - |
dc.subject.keywordPlus | GAMMA-RIII | - |
dc.subject.keywordPlus | EMICIZUMAB PROPHYLAXIS | - |
dc.subject.keywordPlus | CD20 IMMUNOTHERAPY | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.